Vorob'eva M S, El'bert L B, Grachev V P, Lelikov V L, Pervikov Iu V
Vopr Virusol. 1983 Sep-Oct;28(5):622-6.
Human reactogenicity and immunological efficacy of concentrated purified tick-borne encephalitis (CTBEV) vaccine was studied in a controlled trial. The new vaccine was found to be superior to the commercial preparation in its capacity to induce specific humoral and cell-mediated immunity in man and in reduced sensitizing activity with regard to nonviral cellular antigens. Two vaccinations with CTBEV in doses of 0.5 ml each at 6-month interval are recommended. At this vaccination schedule virus neutralizing antibodies were detectable in 95% vaccines. Inoculation of 0.5 ml CTBEV is accompanied by fever of mild and moderate intensity in 19% and 3% of the vaccines, respectively. In this respect CTBEV is less reactogenic than the commercial preparation.
在一项对照试验中研究了浓缩纯化蜱传脑炎疫苗（CTBEV）的人体反应原性和免疫效力。发现这种新疫苗在诱导人体特异性体液免疫和细胞介导免疫的能力以及降低对非病毒细胞抗原的致敏活性方面优于市售制剂。建议每隔6个月接种两剂CTBEV，每剂0.5毫升。按照这个接种程序，95%的接种者可检测到病毒中和抗体。接种0.5毫升CTBEV时，分别有19%和3%的接种者出现轻度和中度发热。在这方面，CTBEV的反应原性低于市售制剂。
